Today, the U.S. Food and Drug Administration approved Rebyota, the first fecal microbiota product approved by the agency. Rebyota is approved for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years […]
BRISBANE, Australia – Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to announce that leading medical diagnostics provider Sonic Healthcare Limited (ASX: SHL) (“Sonic”) has agreed to invest $17.8m to acquire a […]
Proge Farm, an Italian pharmaceutical company, has made microbiome history with its recently approved therapeutic and will now be able to market its drug based on Lactobaccilus plantarum P 17630. The company obtained authorization from […]
Holobiome and AsiaBiome announce that they have closed a transaction for the acquisition of AsiaBiome by Holobiome. This acquisition unites two innovative life sciences companies that are committed to finding solutions to promote health through […]
Eligo Bioscience announced the issuance by the US Patent and Trademark Office (USPTO) of the first patent in a wide family covering genetic engineering of a key skin microbiome species, Cutibacterium acnes, to support therapeutic […]
BiomeBank today announced the first regulatory approval for a donor derived microbiome drug product worldwide. The Therapeutic Goods Administration (TGA) approved BiomeBank’s product for restoration of gut microbiota in the treatment of recurrent Clostridioides difficile […]
SYNLAB, the leader in medical diagnostic services and specialty testing in Europe, and Microba Life Sciences (Microba), a global leader in the analysis of complex gut microbiomes, have expanded their strategic agreement to broaden geographic […]
By 2028 the global skin care market is projected to near $145.82 billion1, #skincareproducts2 has two billion plus views and counting on TikTok, and Vogue’s 2022 skin care trends3 include “supporting the skin’s microbiome.” The fascination with skin […]
Lonza, a preferred partner to the pharmaceutical, biotech and nutraceutical markets, has launched an innovative new capsule solution for intestinal (enteric) drug delivery. The Capsugel® Enprotect™ capsule does not disintegrate during stomach transit and only […]
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for investigational oral microbiome therapeutic SER-109 for […]
Regulatory requirements are not yet clearly defined due to the relative novelty of LBPs. In addition, there is an inherent lack of straightforward biomarkers in microbiome research, which can make it problematic to link LBPs […]